HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis.

Abstract
Rationale: MicroRNAs are known to influence the development of a variety of cancers. Previous studies revealed that miR-1291 has antiproliferative functions in cancer cells. Carnitine palmitoyltransferase 1C (CPT1C) has a vital role in mitochondrial energy metabolism and modulation of cancer cell proliferation. Since both miR-1291 and CPT1C regulate tumor cell metabolism and cancer progression, we hypothesized that they might be regulated synergistically. Methods: A series of cell phenotype indicators, such as BrdU, colony formation, cell cycle, ATP production, ROS accumulation and cell ability to resist metabolic stress, were performed to clarify the effects of miR-1291 and ERRα expression on tumor cell proliferation and metabolism. A xenograft tumor model was used to evaluate cell tumorigenesis. Meta-analysis and bioinformatic prediction were applied in the search for the bridge-link between miR-1291 and CPT1C. RT-qPCR, western-blot and IHC analysis were used for the detection of mRNA and protein expression. Luciferase assays and ChIP assays were conducted for in-depth mechanism studies. Results: The expression of miR-1291 inhibited growth and tumorigenesis as a result of modulation of metabolism. CPT1C expression was indirectly and negatively correlated with miR-1291 levels. ESRRA was identified as a prominent differentially expressed gene in both breast and pancreatic cancer samples, and estrogen-related receptor α (ERRα) was found to link miR-1291 and CPT1C. MiR-1291 targeted ERRα and CPT1C was identified as a newly described ERRα target gene. Moreover, ERRα was found to influence cancer cell metabolism and proliferation, consistent with the cellular changes caused by miR-1291. Conclusion: This study demonstrated the existence and mechanism of action of a novel miR-1291-ERRα-CPT1C cancer metabolism axis that may provide new insights and strategies for the development of miRNA-based therapies for malignant cancers.
AuthorsYixin Chen, Yanying Zhou, Fangwei Han, Yingyuan Zhao, Meijuan Tu, Yongtao Wang, Can Huang, Shicheng Fan, Panpan Chen, Xinpeng Yao, Lihuan Guan, Ai-Ming Yu, Frank J Gonzalez, Min Huang, Huichang Bi
JournalTheranostics (Theranostics) Vol. 10 Issue 16 Pg. 7193-7210 ( 2020) ISSN: 1838-7640 [Electronic] Australia
PMID32641987 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
Copyright© The author(s).
Chemical References
  • MIRN1291 microRNA, human
  • MicroRNAs
  • Receptors, Estrogen
  • CPT1B protein, human
  • Carnitine O-Palmitoyltransferase
Topics
  • Animals
  • Breast (pathology)
  • Breast Neoplasms (genetics, pathology)
  • Carcinogenesis (drug effects, genetics)
  • Carnitine O-Palmitoyltransferase (genetics)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects, genetics)
  • Energy Metabolism (genetics)
  • Female
  • Gene Expression Regulation, Neoplastic (drug effects)
  • HEK293 Cells
  • Humans
  • Male
  • MicroRNAs (antagonists & inhibitors, metabolism)
  • Mitochondria (metabolism)
  • Pancreas (pathology)
  • Pancreatic Neoplasms (genetics, pathology)
  • Receptors, Estrogen (genetics, metabolism)
  • Xenograft Model Antitumor Assays
  • ERRalpha Estrogen-Related Receptor

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: